Answers are grounded in this paper and cite their sources.
Background The Food and Drug Administration (FDA) Patient-Focused Drug Development (PFDD) Draft and Final Guidance 3 provide depictions of conceptual frameworks incorporating conceptual and measurement models for all clinical outcome assessment (COA) types; however, operational guidance for framework development is limited. Members of the International Society for Quality of Life Research (ISOQOL) Industry Special Interest Group (I-SIG) investigated current practices and perspectives to identify and disseminate key considerations for the development of conceptual frameworks to support COAs for regulatory submissions. Methodology Using an online survey of I-SIG members, the authors investigated current perspectives and practices addressing four key conceptual framework development topics: use of theoretical health/disease experience models/frameworks; conceptual model comprehensiveness; selection of COA type(s); and effective collaboration for conceptual model development. Results From 24 I-SIG survey respondents, several key considerations emerged (≥67% respondent agreement). Most respondents endorsed using published theoretical models/frameworks of health and/or behavior to support the development of conceptual models or COA strategies for clinical trials ( n = 19/24; 79%). These published models/frameworks were used to identify concepts of interest (COIs) that may be used to develop a measurement model using a COA and/or other strategy ( n = 16/19; 84%), and most respondents ( n = 18/22; 82%) recommended using a published model/framework in regulatory submissions. The majority of respondents disagreed that conceptual models should include only concepts reported “spontaneously” ( n = 19/24; 79%). Respondents determined which COI(s) warrants development of a measurement model based on each COI’s relevance to patients ( n = 16/20; 80%). The type of COA selected for evaluation of a COI depends upon the assessed COI ( n = 22/22; 100%), whether the COI is observable ( n = 21/22; 95%), characteristics of the target population ( n = 20/22; 91%), availability of existing measures ( n = 15/22; 68%), and if inclusion of more than one COA for the same COI is warranted ( n = 16/19; 84%). Finally, respondents advocated for effective conceptual model development that incorporates patient stakeholders ( n = 17/17; 100%), each with a role and commitment to capture the patient experience through their unique perspective, and healthcare professionals who regularly interact with patients ( n = 15/17; 88%). Conclusion This investigation’s guidance-generating considerations provide practical insights for developing conceptual frameworks used in medical product development.
No takes yet. Share an insight, caveat, or question.
Wyrwich et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: